Article Contents ::
- 1 The Brand Name ADVACAN Has Generic Salt :: EVEROLIMUS
- 2 ADVACAN Is From Company Biocon Priced :: Rs. 600
- 3 ADVACAN have EVEROLIMUS is comes under Sub class Anti Neoplastic Agents of Main Class Anti Neoplastic Agents
- 4 Main Medicine Class:: Anti Neoplastic Agents Sub Medicine Class :: Anti Neoplastic Agents
- 5 Disclaimer ::
- 6 The Information available on this site is for only Informational Purpose , before any use of this information please consult your Doctor .Price of the drugs indicated above may not match to real price due to many possible reasons may , including local taxes etc.. These are only approximate indicative prices of the drug.
The Brand Name ADVACAN Has Generic Salt :: EVEROLIMUS
ADVACAN Is From Company Biocon Priced :: Rs. 600
ADVACAN have EVEROLIMUS is comes under Sub class Anti Neoplastic Agents of Main Class Anti Neoplastic Agents
Main Medicine Class:: Anti Neoplastic Agents Sub Medicine Class :: Anti Neoplastic Agents
|Salt Name : OR Generic Name||Form||Price : MRP /Probable||Packing|
Indications for Drugs ::
Breast cancer, Kidney cancer, Renal transplant, Liver transplant, Neuroendocrine tumors, Renal cell carcinoma, Astrocytoma, Renal angiomyolipoma,Tuberous sclerosis
Drug Dose ::
PO: Advanced HR+ BC, advanced PNET, advanced RCC, or renal angiomyolipoma with TSC: 10 mg once daily with or without food
Patients with hypersensitivity to the active substance, to other rapamycin derivatives, or to any of the excipients. Hypersensitivity reactions manifested by symptoms including, but not limited to, anaphylaxis, dyspnea, flushing, chest pain, or angioedema (e.g., swelling of the airways or tongue, with or without respiratory impairment) have been observed with everolimus and other rapamycin derivatives
Drug Precautions ::
Non-infectious pneumonitis is a class effect of rapamycin derivatives, . Non-infectious pneumonitis was reported in up to 19% of patients treated in clinical trials. The incidence of Common Terminology Criteria (CTC) grade 3 and 4 non-infectious pneumonitis was up to 4.0% and up to 0.2%, respectively
Drug Side Effects ::
Management of severe or intolerable adverse reactions may require temporary dose reduction and/or interruption of therapy. If dose reduction is required, the suggested dose is approximately 50% lower than the daily dose previously administered [see Warnings and Precautions (5)]. Table 1 summarizes recommendations for dose reduction, interruption or discontinuation of in the management of adverse reactions. General management recommendations are also provided as applicable. Clinical judgment of the treating physician should guide the management plan of each patient based on individual benefit/risk assessment.
Pregnancy category ::
Drug Mode of Action ::
Everolimus, a proliferation signal inhibitor, prevents allograft rejection in rodent and nonhuman primate models of allotransplantation. It exerts its immunosuppressive effect by inhibiting the proliferation and thus, clonal expansion, of antigen-activated T cells which is driven by T cell-specific interleukins eg, interleukin-2 and interleukin-15. Everolimus inhibits an intracellular signaling pathway that normally leads to cell proliferation when triggered by the binding of these T cell growth factors to their receptors. The blockage of this signal by everolimus causes cells to be arrested at the G1 stage of the cell cycle. At the molecular level, everolimus forms a complex with the cytoplasmic protein FKBP-12. In the presence of everolimus, the growth factor-stimulated phosphorylation of the p70 S6 kinase is inhibited. Since p70 S6 kinase phosphorylation is under the control of FRAP (also called m-TOR), this finding suggests that the everolimus-FKBP-12 complex binds to and thus, interferes with the function of FRAP. FRAP is a key regulatory protein which governs cell metabolism, growth and proliferation; disabling FRAP function thus explains the cell cycle arrest caused by everolimus.
Drug Interactions ::
CYP3A4 inhibitors &/or inducers, CYP2D6 substrates w/ narrow therapeutic index, PgP inhibitors, rifampicin, ACE inhibitors, grapefruit juice & live vaccines.